受强制性开放获取政策约束的文章 - Michael Ong了解详情
无法在其他位置公开访问的文章：7 篇
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
J Mateo, M Ong, DSP Tan, MA Gonzalez, JS De Bono
Nature reviews Clinical oncology 10 (12), 688-696, 2013
强制性开放获取政策： Cancer Research UK
AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer–results of two parallel first-in-human phase I studies
A Omlin, RJ Jones, R Van Der Noll, T Satoh, M Niwakawa, SA Smith, ...
Investigational new drugs 33, 679-690, 2015
强制性开放获取政策： Cancer Research UK, Prostate Cancer UK, Swiss Cancer League
Novel drugs targeting the androgen receptor pathway in prostate cancer
J Mateo, A Smith, M Ong, JS de Bono
Cancer and Metastasis Reviews 33, 567-579, 2014
强制性开放获取政策： Cancer Research UK, National Institute for Health Research, UK
Addition of docetaxel to androgen receptor axis–targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network meta-analysis
S Roy, R Sayyid, F Saad, Y Sun, K Lajkosz, M Ong, Z Klaassen, S Malone, ...
European Urology Oncology 5 (5), 494-502, 2022
强制性开放获取政策： US Department of Defense
Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation
BA Keller, BJ Laight, O Varette, A Broom, MÈ Wedge, B McSweeney, ...
Journal of Cancer Research and Clinical Oncology 147, 1365-1378, 2021
强制性开放获取政策： Canadian Institutes of Health Research, Natural Sciences and Engineering …
Recent advances in second-line treatment of castration-resistant prostate cancer
M Ong, E Winquist
Current Opinion in Supportive and Palliative Care 5 (3), 199-205, 2011
强制性开放获取政策： Canadian Institutes of Health Research
An Overview: Current Systemic Therapies for Advanced Non-Small Cell Lung Cancer
M Ong, M D Vincent
Current Respiratory Medicine Reviews 7 (5), 354-363, 2011
强制性开放获取政策： Canadian Institutes of Health Research
可在其他位置公开访问的文章：17 篇
Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study
T Powles, PH O'Donnell, C Massard, HT Arkenau, TW Friedlander, ...
JAMA oncology 3 (9), e172411-e172411, 2017
强制性开放获取政策： US National Institutes of Health
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study
COVIDSurg Collaborative
Anaesthesia 76 (6), 748-758, 2021
强制性开放获取政策： US National Institutes of Health, British Heart Foundation, National …
Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration
JS Frenel, S Carreira, J Goodall, D Roda, R Perez-Lopez, N Tunariu, ...
Clinical Cancer Research 21 (20), 4586-4596, 2015
强制性开放获取政策： Cancer Research UK, UK Medical Research Council, National Institute for …
Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK
AW Tolcher, K Khan, M Ong, U Banerji, V Papadimitrakopoulou, ...
Clinical Cancer Research 21 (4), 739-748, 2015
强制性开放获取政策： US National Institutes of Health, Cancer Research UK, National Institute for …
First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014
B Basu, E Dean, M Puglisi, A Greystoke, M Ong, W Burke, M Cavallin, ...
Clinical cancer research 21 (15), 3412-3419, 2015
强制性开放获取政策： Cancer Research UK, National Institute for Health Research, UK
SARS‐CoV‐2 infection and venous thromboembolism after surgery: an international prospective cohort study
COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ...
Anaesthesia 77 (1), 28-39, 2022
强制性开放获取政策： US National Institutes of Health, British Heart Foundation, National …
A randomised trial of 4-versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
M Clemons, M Ong, C Stober, S Ernst, C Booth, C Canil, M Mates, ...
European Journal of Cancer 142, 132-140, 2021
强制性开放获取政策： US National Institutes of Health, Canadian Institutes of Health Research
Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial
M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, ...
Annals of Oncology 32 (7), 896-905, 2021
强制性开放获取政策： Canadian Institutes of Health Research, Prostate Cancer Canada, Academy of …
Effects of pre‐operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study
COVIDSurg Collaborative, GlobalSurg Collaborative, D Nepogodiev, ...
Anaesthesia 76 (11), 1454-1464, 2021
强制性开放获取政策： British Heart Foundation, National Institute for Health Research, UK …
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail
M Ong, S Carreira, J Goodall, J Mateo, I Figueiredo, DN Rodrigues, ...
British journal of cancer 111 (5), 828-836, 2014
强制性开放获取政策： Cancer Research UK, Prostate Cancer UK
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
J de Bono, CC Lin, LT Chen, J Corral, V Michalarea, K Rihawi, M Ong, ...
British Journal of Cancer 122 (9), 1324-1332, 2020
强制性开放获取政策： National Institute for Health Research, UK
Promoting sleep to improve delirium in the ICU
BB Kamdar, JL Martin, DM Needham, MK Ong
Critical care medicine 44 (12), 2290-2291, 2016
强制性开放获取政策： US National Institutes of Health
Two-year results of a randomised trial comparing 4-versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
M Clemons, M Liu, C Stober, G Pond, MJ Alzahrani, M Ong, S Ernst, ...
Journal of Bone Oncology 30, 100388, 2021
强制性开放获取政策： Canadian Institutes of Health Research
出版信息和资助信息由计算机程序自动确定